Inactive Instrument

ENTREMED Stock Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
14/08	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	2.36M 2.08M 1.97M 1.78M 3.35M 226M 3.39M 23.54M 9.06M 116M 8.85M 8.66M 371M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.21M 21.32M 20.2M 18.24M 34.37M 2.32B 34.82M 242M 93.01M 1.19B 90.92M 88.93M 3.8B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
14/08	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
04/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
04/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

14/08	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
01/07	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news: ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.17%	-2.69%	+39.34%	+113.66%	1,031B
JOHNSON & JOHNSON	-0.83%	-2.87%	+41.31%	+69.46%	638B
ABBVIE INC.	-0.54%	-1.38%	+6.99%	+76.36%	462B
MERCK & CO., INC.	-0.50%	-2.17%	+60.62%	+41.17%	359B
ROCHE HOLDING AG	-0.21%	-3.88%	+23.73%	+40.82%	335B
NOVARTIS AG	-1.68%	-0.34%	+13.98%	+26.98%	273B
ASTRAZENECA PLC	-1.69%	-2.27%	-2.56%	+10.67%	253B
AMGEN INC.	-1.26%	+2.97%	+40.06%	+56.99%	228B
GILEAD SCIENCES, INC.	-0.75%	-0.60%	+33.86%	+100.80%	185B
Average	-0.95%	-0.36%	+28.59%	+59.65%	418.21B
Weighted average by Cap.	-0.92%	-0.35%	+31.46%	+70.92%

	2024	2025
Net sales	28.54M 25.13M 23.81M 21.49M 40.51M 2.74B 41.04M 285M 110M 1.4B 107M 105M 4.48B	20.71M 18.24M 17.28M 15.6M 29.4M 1.99B 29.78M 207M 79.57M 1.02B 77.77M 76.08M 3.25B
Net income	-39.26M -34.57M -32.75M -29.57M -55.73M -3.76B -56.45M -392M -151M -1.92B -147M -144M -6.17B	-48.06M -42.32M -40.1M -36.2M -68.23M -4.61B -69.11M -480M -185M -2.36B -180M -177M -7.55B
Net Debt	6.05M 5.33M 5.05M 4.56M 8.59M 580M 8.7M 60.39M 23.24M 297M 22.72M 22.22M 951M	21.85M 19.24M 18.23M 16.46M 31.03M 2.1B 31.43M 218M 83.95M 1.07B 82.06M 80.27M 3.43B